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Gene silencinga b s t r a c t
The therapeutic application of siRNA suffers from poor bioavailability caused by rapid degradation and
elimination. The covalent attachment of PEG is a universal concept to increase molecular size and
enhance the pharmacokinetic properties of biomacromolecules. We devised a facile approach for attach-
ment of PEG molecules with a deﬁned molecular weight, and successful puriﬁcation of the resulting con-
jugates. We directly conjugated structurally deﬁned PEG chains with twelve ethylene glycol units to the
30-terminal hydroxyl group of both sense and antisense strands via an aminoalkyl linker. The conjugates
were easily puriﬁed by HPLC and successful PEGylation and molecule integrity were conﬁrmed by ESI-
MS. The evaluation of in vitro gene knockdown of two different targets in MCF-7 breast cancer cells
showed stable pharmacologic activity when combined with a standard transfection reagent. Sense strand
PEGylation even increased the silencing potency of a CRCX4-siRNA which had modest activity in its wild-
type form. The results indicate that PEG chains at the 30-terminus of both strands of siRNA are well tol-
erated by the RNAi effector. The attachment of short, chemically deﬁned PEG chains is a feasible approach
to improve the pharmacokinetic properties of siRNA, and can be combined with other targeted and untar-
geted delivery vehicles.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
The development of gene silencing oligonucleotides for thera-
peutic applications has recently seen encouraging results. In early
2013 the ﬁrst systemically applied antisense compound, mipomer-
sen has won market approval in the USA for the treatment of
homozygous familiar hypercholesterolemia.1 Positive clinical re-
sults of the application of splice-switching agents have been re-
ported for the treatment of Duchenne muscular dystrophy
(DMD). Two distinct oligonucleotides, eteplirsen2 and drisapersen3
have resulted in restoration of functional dystrophin protein in hu-
man patients, and improved the clinical outcome. Mipomersen is a
second generation phosphorothioate antisense oligonucleotide
with terminal 20-O-methoxyethyl nucleosides, drisapersen is a
phosphorothioate with ﬂanking 20-O-methoxy nucleosides, and
eteplirsen is a phosphorodiamidate morpholino oligomer (PMO).
siRNA oligonucleotides have not yet been evaluated in compre-
hensive clinical trials, but preclinical development has shown
encouraging results. Because chemical optimization is poorly toler-
ated by the molecular effectors, the main attention has been
shifted to focus on the development of delivery systems. Lipidnanoparticles (SNALPs) have been evolved to increase delivery efﬁ-
ciency and have enabled a signiﬁcant lowering of the dose neces-
sary for intracellular gene silencing.4,5 Other delivery systems
have been designed for decomposition after successful cellular up-
take, enhancing release of the siRNA cargo and facilitating endo-
somal escape.6,7 Using disulﬁde and acid labile bonds, targeting
ligands N-acetyl glucosamine (GalNAc) and masking groups are
cleaved from the carrier polymer in the endsome, resulting in a
positively charged compound believed to destabilize endosomes
through the proton sponge effect.8,9
Despite these progresses, several important challenges remain
before gene silencing oligonucleotides can be applied in a wide-
spread manner in the therapeutic setting. The example of mipom-
ersen shows that the toxicity issue is far from resolved.
Mipomersen has not been granted approval in Europe due to con-
cerns about hepatotoxicity and cardiovascular adverse effects. In
the USA, a risk management and mitigation strategy (REMS) has
been required by the FDA to gather information about adverse ef-
fects in long-term treatment regimens. The phosphorothioate
backbone of antisense oligonucleotides not only mediates plasma
protein binding and triggers a cellular uptake mechanism, but is
also responsible for sequence-unspeciﬁc effects, including apopto-
sis induction and endoplasmatic reticulum stress.10–14 Delivery
systems for siRNA are so far only effective for hepatic gene
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polymers show a high preference for liver tissue.15 At present, no
strategy for effective siRNA delivery to other tissues is available.
A wide variety of oligonucleotide conjugates with ligands for
enhancing bioavailability or adding active targeting have been pre-
pared and evaluated.16 Examples include conjugations with small
lipophilic molecules (cholesterol, fatty acids, etc.), saccharides such
as GalNac, or receptor-targeted peptides and proteins. Addition-
ally, the attachment of short and long polyethylene glycol chains
has been investigated for the ability to increase the apparent
molecular size of oligonucleotides and alleviate their high hydro-
philicity with the aim to increase bioavailability and cell mem-
brane permeation. PEGylation of nucleic acids can most
conveniently be done at the 30- or 50-OH-group, directly or by
introduction of a spacer. It was discovered that this modiﬁcation
extended plasma stability and reduced renal ﬁltration rates.17 An
antisense oligonucleotide conjugate with PEG 5000 was effective
for in vitro and in vivo gene silencing when applied with a polyeth-
ylene imine carrier.18 A PEGylated aptamer, pegaptanib, was ap-
proved by FDA in 2004 for the treatment of age-dependent
maculadegeneration (AMD). Here, a branched PEG of 40 kDa is at-
tached to the VEGF-targeted aptamer through a penta-amino
linker.
For siRNA, PEG chains with molecular weights between 2 and
20 kDa have been attached to the oligonucleotides.19–21 PEGylation
generally reduces the gene silencing activity signiﬁcantly when at-
tached in a non-cleavable manner,20,21 but enhances the pharma-
cokinetic properties. siRNA PEGylation is usually afforded with
polydisperse long-chain PEG mixtures, which yields mixtures of
conjugates with different PEG chain lengths, complicating puriﬁca-
tion and analyses. To avoid those problems, we conjugated short
PEG chains with deﬁned length and size to siRNA sense and anti-
sense strands. We hypothesized that the molecular components
of the RNAi mechanism show better tolerance for shorter PEG
chains then for larger ligands, and by using the 30-hydroxy group
of the sense or antisense strand, inhibition of strand recognition
was aimed to be minimized. We generated a conjugated oligonu-
cleotide with a deﬁned structure, and show that short PEGyl chains
are well tolerated by the molecular siRNA effectors with no
decrease in knockdown efﬁciency.
2. Results
The reaction of an N-hydroxy succinimide (NHS) activated PEG
esters with primary amino groups is an attractive and facile option
for the preparation of PEG-conjugated siRNAs (Fig. 1). We used
amino-on CPG,22 a modiﬁed resin for oligonucleotide synthesis,Figure 1. Reaction scheme of NHS–PEG conjugation. The N-hydroxy succinimide
active ester of a monodisperse PEG with 12 ethylene glycol units was covalently
attached to the 30-aminohexyl linker of a single stranded siRNA oligonucleotide. The
reaction was conducted in borate buffer, pH 8.0, with a 25-fold surplus of PEG–
NHS–ester. After 1 h, the conversion was nearly complete, and isolated yields were
over 75%.to introduce an aminohexyl function to the 30-terminus of both
antisense and sense strand of the siRNA. After employing the rec-
ommended conditions for oligonucleotide cleavage and deprotec-
tion (AMA, 10 min at 65 C), we initially found two different
compounds after puriﬁcation, which were well separated on a
RP-HPLC column, but co-migrated in gel electrophoresis. Mass
spectrometric analysis revealed that the encountered impurity re-
sulted from incomplete deprotection of the amino-on resin22
(Fig. 2). The more labile ester linkage is completely hydrolyzed un-
der these basic conditions, while the amide masking the amin-
ohexyl linker is less reactive, and a mixture of the desired amino
functionalized oligonucleotide and the corresponding 2-(hydroxy-
methyl)-5-nitrobenzamide derivative was isolated. Longer depro-
tection with concentrated ammonia or AMA afforded the
completely deprotected 30-aminohexyl oligonucleotide.
(PEG)12–NHS ester was reacted in an aqueous buffer solution to
the aminohexyl linker in a 25-fold molar surplus, yielding conver-
sion rates of over 75%. Monodisperse PEG chains were successfully
attached to both the sense and antisense strand of a bcl-2 targeted
siRNA. After HPLC puriﬁcation (Fig. 3) and desalting, the conjugate
structure was veriﬁed by ESI-MS (Table 1).
The siRNA conjugates were transfected into mammalian MCF-7
cells and the knockdown of the target bcl-2 mRNA was initially
investigated with a luciferase reporter assay. We inserted the cDNA
of the human bcl-2 gene into the plasmid by molecular cloning,
affording a quantitative readout for gene silencing activity (Renilla)
with normalization to the second luciferase gene (Fireﬂy). The
plasmid was co-transfected with the respective siRNA, and Renilla
and Fireﬂy luciferase levels were detected after addition of the
appropriate substrates. The siRNA PEGylated on both strands
(5+6) resulted in strong gene silencing (Fig. 4), with potent activity
of over 70% already in a nanomolar concentration, and a reduction
of nearly 90% of the reporter gene after treatment with 100 nM.
Compared to the unmodiﬁed sequence (1+2), the extent of bcl-2
knockdown was not reduced by PEGylation.Figure 2. Side product after incomplete deprotection of amino-on CPG. The
recommended reaction time for oligonucleotide resin cleavage of 10 min in AMA
at 65 C proved to be insufﬁcient for complete deprotection of the amino function of
the amino-on CPG. The nitrophenyl amide was found to be still partially attached. A
second deprotection step of the mixture in concentrated ammonia for 4 h provided
a homogenous solution of the oligonucleotide with free primary amine. Alterna-
tively the amino-on CPG can be completely deprotected by longer incubation in
AMA.
Figure 3. HPLC of PEGylated antisense strand (5) after puriﬁcation. Semi-preparative reversed phase HPLC with a linear gradient of acetonitrile (8–30% in 30 min) in TEAA
buffer was used for separation of PEGylated siRNA oligonucleotides 5 and 6 from unreacted educts (3 and 4) and NHS-PEG12. Analytical HPLC of the respective fractions with
the same conditions conﬁrmed the successful puriﬁcation and high purity of the isolated compound.
Table 1
Sequences and ESI-MS data of bcl-2 (1–6) and CXCR4 (7 and 8) targeted siRNA oligonucleotides
Oligonucleotide sequence Strand Modiﬁcation Mass calcd Mass found
1 UCA-GGU-ACU-CAG-UCA-UCC-ACA-dTdT AS — 7224.14 7224.03
2 UGU-GGA-UGA-CUG-AGU-ACC-UGA-dTdT S — 7361.22 7362.16
3 UCA-GGU-ACU-CAG-UCA-UCC-ACA-dTdT AS 30-Amino 7403.21 7403.26
4 UGU-GGA-UGA-CUG-AGU-ACC-UGA-dTdT S 30-Amino 7540.29 7540.15
5 UCA-GGU-ACU-CAG-UCA-UCC-ACA-dTdT AS 30-PEG 7974.54 7974.14
6 UGU-GGA-UGA-CUG-AGU-ACC-UGA-dTdT S 30-PEG 8111.62 8110.93
7 AAA-CUC-ACA-CCC-UUG-CUU-GdTdT AS —
8 CAA-GCA-AGG-GUG-UGA-GUU-UdTdT S —
9 AAA-CUC-ACA-CCC-UUG-CUU-GdTdT AS 30-PEG
10 CAA-GCA-AGG-GUG-UGA-GUU-UdTdT S 30-PEG
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ed at either the sense (1+6) or both strands (5+6) were transfected
into MCF-7 cells and the levels of endogenous bcl-2 were quanti-
ﬁed by RT-qPCR. In correlation to the reporter assay, the attach-
ment of short PEG chains had no detrimental effect of gene
silencing activity (Fig. 5A). No statistically signiﬁcant differences
were detected between siRNAs with one PEG molecules at the
sense or two PEG chains at both strands. After lipofectamine med-
iated transfection in a 1 nM concentration, the bcl-2 levels were re-
duced to 7–10%, and with 10 nM to 2–4% relative to untreated
control samples.
For examination of a cell membrane permeation enhancing ef-
fect of the PEG-siRNAs, we also applied them in absence of any
transfection agent. However, bcl-2 mRNA levels were unaltered
(Fig. 5B), indicating that no unassisted uptake of these conjugates
takes place.
The bcl-2 siRNA is highly active already in its unmodiﬁed state,
and results in a 10-fold reduction of the corresponding mRNA. We
hypothesized that the effect of PEGylation may be higher in cases
where the down regulation effect of unmodiﬁed siRNA is only
modest. To this end, we prepared a PEG conjugate of an siRNA tar-
geted at CXCR4, a CXC chemokine receptor speciﬁc for stromal cell-
derived factor-1.23 The wild-type siRNA results in a modestreduction of the CXCR4 mRNA to 27% when applied at a concentra-
tion of 2 nM. The siRNA duplex with only the antisense strand
PEGylated showed nearly identical activity (Fig. 6). When both
strands were modiﬁed, the targeted mRNA level was reduced to
21%, and with only the sense strand PEGylated, the effect was in-
creased and resulted in a reduction to 17%, a statistically signiﬁcant
higher activity compared to the unmodiﬁed compound.
3. Discussion
Previously reported PEGylation strategies of antisense, aptamer
or siRNA oligonucleotides relied on long linear or branched poly-
ethylene glycols. The primary purpose of PEGylation is to achieve
an increase in circulation time by reduction of renal ﬁltration,
and masking of immunostimulatory effects of modiﬁed oligonucle-
otides.17 In the case of pegaptanib, two 20 kDa PEG chains are
attached to the aptamer to ensure retention at the intravitreal
injection site.24,25 Nearly all reports of PEGylated antisense
oligonucleotides used long PEG chains, usually in the range of
20–40 kDa, equivalent of around 450–900 ethylene glycol mono-
mers.26,27 As an example, the PEGylation of oblimersen, a 20mer
phosphorothioate antisense agent, resulted in a strong reduction
of in vitro uptake in combination with lipofectamine transfection,
Figure 4. Gene knockdown in a luciferase reporter assay after co-transfection of
psiCHECK2-bcl-2 plasmid and siRNA. A psiCHECK2 plasmid with the cDNA of the
human bcl-2 gene fused to the Renilla luciferase gene was transfected together with
the indicated siRNA into MCF-7 breast cancer cells. Bcl-2 targeted gene knockdown
reduces the signal of the Renilla luciferase, while the Fireﬂy luciferase is used for
normalization of transfection efﬁciency and cell number. Knockdown effects are
reported in normalized Renilla luciferase intensities (n = 3), error bars represent the
standard deviation.
Figure 5. Gene knockdown of endogenous bcl-2. (A) After lipofectamine 2000-
mediated transfection, (B) after unassisted application. The effect of PEG-siRNA
conjugates (siRNA-PEG (S), 1/6; siRNA-PEG2 (S/AS), 5/6) was evaluated by qPCR-
based quantiﬁcation of bcl-2 mRNA levels in MCF-7 cells. The indicated siRNAs
were either transfected into the cells with lipofectamine 2000 (A), or applied
without any uptake-enhancing agent (B). Cells were lysed after 24 h, total RNA was
extracted, transcribed into cDNA, and quantiﬁed with qPCR. Bcl-2 levels were
normalized to the reference gene RNA polymerase II, which was shown not to be
inﬂuenced by siRNA or the transfection procedure. After lipofectamine-mediated
delivery, efﬁcient gene silencing occurred with both modiﬁed and unmodiﬁed
siRNAs (p < 0.05 compared to untreated cells) with virtually no difference between
PEGylated (1/6 and 5/6) and non-PEGylated siRNA (1/2) duplexes. In contrast, no
gene silencing was detected when either of the siRNAs were applied without
transfection enhancing agent, indicating no unassisted (gymnotic) uptake takes
place. All values are reported relative to untreated cells (n = 3), error bars represent
the standard deviation.
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explained by a constant release of the active antisense agent by
cleavage of the PEG chain.
For siRNA applications, PEGylation of siRNA at the 30- or 50-po-
sition has been reported with polydisperse PEG chains of an aver-
age molecular weight between 5 and 20 kDa.19–21 One study
reported a decrease in silencing efﬁciency of a VEGF-targeted oligo-
nucleotide compared to naked siRNA when PEG 5k was attached
using a non-cleavable maleimide linker.20 In contrast, the applica-
tion of a disulﬁde tether, which is expected to be cleaved in the
endosome after successful uptake, resulted in minimized reduction
of the gene silencing effect. PEGylation was tolerated on 30- and
50-ends of both strands, and after transfection with standard
reagents, the extent of target down regulation was slightly lower
to that achieved with unmodiﬁed siRNA. In a recent study, PEG
with average molecular weights of 5, 10, and 20 kDa were attached
to an LNA-modiﬁed siRNA at the 50-end of the sense strand via click
chemistry.21 Knockdown efﬁciencies of 50–60% were found for
PEGylated siRNA, while the unmodiﬁed compound was consider-
ably more effective with 90% reduction of the target gene. In both
cases, the reduced silencing activity was attributed not to de-
creased cellular uptake, but rather to interference with the interac-
tion of siRNA to the modulating RNAi enzymes dicer and RISC.20
The reduction in potency was proportional to the length of the
PEG chains.21 The main virtue of PEGylation is the prolongation
of circulation time by reducing the renal ﬁltration rates, and the
20 kDa PEG-siRNA conjugate showed an increase in blood half-live
from 5 min to 1 h.21
Consequently, we aimed to evaluate the gene silencing activity
of conjugates of siRNA with short PEG ligands. We conjugated
monodisperse Me-(PEG)12, affording the generation of a molecule
with deﬁned structure and molecular weight. PEGylation with high
molecular weight ligands is only possible with a complex mixture
of PEG chains of different length, yielding polydisperse conjugates,
which in turn complicates chromatographic and mass spectrome-
try analyses as well as biological evaluations.28 The reaction
of NHS–PEG with amino-modiﬁed single stranded RNAoligonucleotides afforded nearly complete conversion of the oligo-
nucleotide after 3 h at room temperature in a borate buffer as mon-
itored by HPLC. Ligand attachment at the siRNA is commonly
preferred at the sense strand, because of minor interference with
RISC strand recruitment and mRNA cleavage.16 Small molecule li-
gands attached at the 50-end of the antisense strand have been
shown to cause detrimental effects on gene silencing activity.
The attachment of the amino linker at the 30-position was achieved
by the use of a commercially available modiﬁed CPG resin.22
Figure 6. Gene knockdown of endogenous CXCR4. The effect of PEG-siRNA
conjugates (siRNA-PEG (S), 7/10; siRNA-PEG (AS), 9/8; siRNA-PEG2 (S/AS), 9/10)
was evaluated by qPCR-based quantiﬁcation of CXCR4 mRNA levels in MCF-7 cells.
The indicated siRNAs were transfected into the cells at a concentration of 2 nM with
lipofectamine 2000. Cells were lysed after 24 h, total RNA was extracted,
transcribed into cDNA, and quantiﬁed with qPCR. All compounds resulted in
efﬁcient reduction of mRNA levels compared to untreated cells (p < 0.05, n = 3).
When only the sense strand was PEGylated, statistically signiﬁcant enhancement of
the gene silencing effect was detected. Error bars represent the standard deviation, ⁄
denotes p < 0.05 compared to cells treated with the unmodiﬁed siRNA.
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ﬁed to ensure complete deprotection of the amino group. The con-
ditions recommended from the manufacturer proved to be
insufﬁcient for cleavage of the nitrophenyl masking group, and
the respective impurity, the identity of which was conﬁrmed by
ESI-MS, was detected in up to 50% amount in HPLC traces.
After successful conjugation, the PEGylated RNA oligonucleo-
tides were easily puriﬁed by semi-preparative RP-HPLC, taking
advantage of the higher retention time of the PEGylated product.
Initial evaluation of the gene silencing potency was performed
with a luciferase reporter assay. To be able to monitor the activity
of the bcl-2 targeted siRNA, we generated a psiCHECK2 plasmid
with the bcl-2 cDNA inserted before the stop codon of Renilla lucif-
erase. The luciferase reporter assay showed signiﬁcant and potent
bcl-2 down regulation by PEG-siRNA conjugates with standard
lipofectamine transfection. Remarkably, no statistically signiﬁcant
differences resulted between siRNA PEGylated at either the sense
or both sense and antisense strand, and the unmodiﬁed oligonu-
cleotide. The shorter PEG chain is obviously better tolerated by
the RNAi effector molecules than PEG 5 or 10 kDa,20,21 which re-
sulted in reduced silencing potency.
The effects on the endogenous bcl-2 levels were investigated by
qPCR analyses after treatment of MCF-7 cells with PEGylated siRNA
in the presence and absence of a transfection enhancer. Conﬁrming
the results generatedwith the luciferase reporter system,we founda
potentmRNA knockdown for two different gene targets. PEGylation
of either the sense or both strands did not have any negative inﬂu-
ence on the effect, proving the compatibility of short PEG with the
RNAi effectors. Encountered differences of gene silencing potency
betweenunmodiﬁedandPEGylated siRNAwere slimanddependent
on the gene target. Statistically signiﬁcant enhancements through
the PEG chains were only found in a single case: When using a du-
plex of PEGylated sense and unmodiﬁed antisense (10+8) targeted
at CXCR4, the knock down activity increased. The CXCR4 gene is a
chemokine receptor and has recently attracted attention as a prog-
nostic factor for disease relapse and survival in leukemia patients.It is involved in tumor chemoresistance and a target for increasing
chemosensitivity. In contrast to the highly active anti-bcl-2 siRNA
(1+2), the wild-type CRCX4-targeted sequence (7+8) is only moder-
ately efﬁcient with a depletion of the corresponding mRNA of less
than 74%. This value leaves some room for improvement, and the
sense conjugate duplex (7+10) showed enhanced potency (83%
mRNA reduction). A similar effect is arguably inherently impossible
for those sequences that are already highly efﬁcient in their unmod-
iﬁed form, as is the case for the bcl-2 targeted siRNA 1+2.
No silencing effect was detected when the conjugates were ap-
plied without lipoplexes. In some cases, an increase in cellular up-
take by PEGylation of oligonucleotides with long-chain PEG was
reported,26,29 but others have shown equal21 or even poorer27
membrane permeation. The uptake seems to be dependent on cell
type, and PEGylated oligonucleotides (having a large molecular
weight) are supposedly being taken up by macropinocytosis. Cellu-
lar uptake and particularly endosomal escape is regarded as being
pivotal for successful siRNA therapy, but no chemical modiﬁcation
or ligand conjugation has so far convincingly improved these prop-
erties. The ﬁnding that the conjugates are active siRNA agents and
in some cases enhances their potency is encouraging for further
development and combination with liposomal or nanoparticulate
delivery systems.
4. Conclusion
Although the PEG-siRNA conjugates are arguably too small to
support a signiﬁcant reduction in plasma clearance, the ﬁnding
that the activity is retained and in some cases even enhanced is
encouraging. The conjugation protocol is fully compatible with
other chemical modiﬁcations for increasing stability, such as
20-methylation and phosphorothioate backbones. The short PEG
chain may serve as a handle for interaction with PEGylated deliv-
ery systems, including lipoplexes and nanoparticles.18 In addition,
the attachment of targeting molecules thorough a PEG spacer is a
feasible possibility for improving the pharmacokinetic parameters,
because the conjugation chemistry has no effect on the pharmaco-
logic potency.
5. Materials and methods
5.1. Oligonucleotide synthesis
Synthesis of the anti-Bcl-2-siRNA was performed on the Poly-
Gen 10 column DNA/RNA synthesiser (Polygen) using standard
protocols with 15 min coupling time, 20-O-tert-butyl-trimethylsilyl
(TBDMS) nucleoside phosphoramidites and dicyanoimidazol (DCI)
activator. For attaching an amino linker at the 30 terminus, ami-
no-on-CPG was used, and the ﬁrst nucleotide was coupled on the
synthesizer. All oligonucleotide synthesis reagents were purchased
from SAFC-Proligo (Hamburg, Germany).
After the oligonucleotide assembly, the solid support was trans-
ferred into a vial and incubated with 1 ml of AMA (methanolic
methylamine/NH4OH; 1:1) for 10 min at 65 C. Because of incom-
plete deprotection of the aminohexyl linker, the cleavage condi-
tions were later changed to reaction with ammonia for 4 h at
55 C. The supernatant was collected in a sterile tube. The support
was rinsed twice with 100 ll of RNase-free water. Subsequently
the samples were dried under vacuum (Christ Speed-Vac RVC-2-
18). The dried oligonucleotides were dissolved in 50 ll anhydrous
DMSO (dimethylsulfoxide), 50 ll of TEA⁄3 HF were added and the
mixture was heated to 65 C for 2.5 h.
Oligonucleotides were precipitated by addition of 200 ll so-
dium acetate (0.3 M) and 1 ml butanol. After incubation for
20 min 70 C, the samples were centrifuged for 10 min at
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twice in 750 ll cold 75% ethanol. The supernatant was again dec-
anted and the dried pellet was dissolved in 50 ll RNase free water
for absorption measurement (Nanodrop-1000, Thermo Fisher Sci-
entiﬁc, Waltham, MA, USA). The concentration of siRNA was calcu-
lated according to the Lambert–Beer law with extinction
coefﬁcients calculated from nearest neighbor values.30 The oligo-
nucleotides were diluted to a concentration of 100 lM and stored
at 80 C. siRNA duplexes were obtained by heating equivalent
amounts of antisense and sense strands to 65 C for 3 min followed
by cooling down to room temperature.
5.2. Conjugation of siRNA with polyethylene glycol
A solution of single stranded RNA oligonucleotide (20 nM) was
diluted to 100 ll in 100 mM sodium borate buffer (pH 8.0). 4 ll of
a 250 mM solution of Me(PEG)12–NHS (Pierce, Thermo Scientiﬁc,
Rockford, IL, USA) stock solution in DMF was added. The mixture
was stirred for 1 h at room temperature and the reaction was mon-
itored with HPLC or gel electrophoresis.
5.3. Polyacrylamide gel electrophoresis
One nanomole of each sample was diluted with 10 ll formam-
ide loading buffer. The samples were heated for 3 min at 95 C be-
fore being loaded onto the gel. The gel was run for 1.5 h at 150 V.
For band visualization, the gel was agitated in a 2% solution of
methylene blue for 30 min and subsequently destained with water.
The gel was scanned with a densitometer (Bio-Rad GS-710, Carls-
bad, CA, USA) and analyzed with Quantity One 4.6.3 1-D Analysis
Software (Bio-Rad).
5.4. High performance liquid chromatography (HPLC)
All HPLC runs were performed with a LaChrom L-7100 (Merck
Hitachi) system equipped with a Clarity 5 micron Oligo-RT
250  4.6 mm column (Phenomenex, Aschaffenburg, Germany)
and the EZ Chrome Elite software. For analytical and semi-prepara-
tive runs, a linear gradient of 5–30% acetonitrile in triethylammo-
nium acetate (TEAA) buffer in RNase-free water during 30 min was
used at a ﬂow rate of 1 ml/min. After a semi-preparative run, the
fractions containing the separated oligonucleotides were dried,
and diluted RNase free water.
5.5. Electrospray ionization mass spectrometry (ESI-MS)
Samples formass spectrometrywere desalted by ethanol precip-
itation from ammonium acetate.31 30 ll of a 25 lM siRNA sample
were mixed with 15 ll of a 7.5 M ammonium acetate solution and
left at room temperature for 1 h. After adding 115 ll of ethanol the
samples were left overnight at 80 C. The samples were centri-
fuged for 30 min at 17,400g and 0 C to collect the precipitated oli-
gonucleotides. The ethanol was decanted immediately after
centrifugation and the remaining pellet was washed with 100 ll of
ice cold 75% ethanol and centrifuged for 20 min. The supernatant
was again decanted instantly, the pellet was air-dried and dissolved
in 32 ll of RNase free water. For MS analyses, the samples were di-
luted in acetonitrile and triethylamine to obtain a ﬁnal ratio of
50:50:1 (water/ACN/TEA). Analysis was performed on a micrO-
TOF-Q II 10240 (Bruker, Billerica,MA,USA). Calibrationof the system
was carried out with lithium-formate. The samples were measured
in negative ion mode.
5.6. psiCHECK-2 Bcl-2 plasmid
The psiCHECK-2-vector, obtained from Promega GmbH
(Madison, WI, USA), was digested with EcoRI (Fermentas, ThermoScientiﬁc, Waltham, MA, USA), and converted to a Gateway desti-
nation vector using a Gateway Vector Conversion System (Invitro-
gen, Life Technologies, Paisley, UK) by ligating the reading frame
cassette according to the manufacturer’s instructions. The resulting
destination vector was sequenced to conﬁrm correct orientation of
the reading frame cassette. The human bcl-2 ORF shuttle expres-
sion clone with a Gateway entry vector was obtained from ImaG-
enes (Source BioScience, Berlin, Germany). The psiCHECK2-bcl-2
plasmid was generated by an LR recombination reaction and trans-
formed into Escherichia coli XL1-Blue. The vector was sequenced to
conﬁrm successful cloning, and isolated from E. coli XL1-Blue using
a GeneJET™ Plasmid Miniprep Kit (Fermentas, Thermo Scientiﬁc).
200 ll of an E. coli XL-1 Blue stock were transformed by heat-
shock with 100 ng psiCHECK-2-bcl-2 plasmid and plated onto an
ampicillin agar-plate. Miniprep cultures were grown from a single
colony. The plasmid was isolated with the GeneJET Plasmid Mini-
prep Kit (Fermentas, Thermo Scientiﬁc) according to the manufac-
turer’s instructions.
5.7. Cell cultivation and seeding
Cells were cultivated in Dulbecco’s Modiﬁed Eagle Medium
(DMEM) with GlutaMAX™ (Gibco, Life Technologies, Carlsbad,
CA, USA) supplemented with 10% FBS (PAA, Pasching, Austria) at
37 C in 5% CO2. The cell line MCF-7 was obtained from the Euro-
pean cell culture collection (EACC). Cells were trypsinized and
resuspended in an appropriate volume of preheated culture med-
ium, and counted with a Neubauer chamber. 3  104 cells were
plated in 96-well plates for the luciferase assays, and 1  105 cells
were used in a 24 well plates for qPCR assays. Each treatment was
performed in triplicate.
5.8. Dual-luciferase reporter assay
For reverse co-transfections, a mix of including the psiCHECK2-
bcl-2 plasmid (100 ng/well), the siRNA 0.1–10 pMol/well) and
Lipofectamine™2000 (0.25 ll/well) was prepared in Opti-MEM
(50 ll/well) according to the manufacturer’s instructions. The
transfection mixture was pipetted into the multiwell plate and
incubated at room temperature for 20 min before the cell suspen-
sion (100 ll per well) was added. Cells were incubated for 48 h.
For the assessment of unassisted uptake of the conjugates, amix-
ture of the psiCHECK2-bcl-2 plasmid (100 ng/well), and Lipofect-
amine™2000 (0.25 ll/well) was prepared in Opti-MEM (50 ll/
well) according to themanufacturer’s instructions. The transfection
mixture was pipette into themultiwell plate and incubated at room
temperature for 20 min before the cell suspension was added. After
24 h of incubation the medium was removed, and the indicated
amount of siRNA diluted in 100 ll DMEM with 10% FCS was trans-
ferred to each well. Cells were incubated for a further 48 h.
For the luminescence-based quantiﬁcation of gene knockdown,
the Dual Luciferase Assay (Promega, Madison, WI, USA) was used
according to the manufacturer’s instructions. The cell medium
was removed, cells were washed with PBS, and lysed for 20 min
at rt with 20 ll lysis buffer per well. The substrates were dispensed
using the plate reader’s (Tecan inﬁnite M200Pro) injector and the
luminescence was measured immediately. For normalization of
transfection efﬁciency and cell growth, the ratio of renilla and ﬁre-
ﬂy luciferase was calculated.
5.9. RNA extraction and cDNA synthesis
After 48 h incubation the whole RNA was extracted. Column
based RNA extraction was performed according to the GeneJET
RNA Puriﬁcation Kit (Fermentas, Thermo Scientiﬁc) manufacturer
manual. The concentration and purity of the extracted RNA was
2326 Z. Gaziova et al. / Bioorg. Med. Chem. 22 (2014) 2320–2326determined with a Nanodrop spectrophotometer. Five-hundred
nanograms total RNA of each sample were used for cDNA synthesis
with the RevertAid First Strand cDNA Synthesis Kit (Fermentas,
Thermo Scientiﬁc) with a random hexamer primer in an Eppendorf
Thermo Cycler according to the manufacturer’s instructions.
Two microliter of 1:10 diluted cDNA were used for each qPCR
reaction. The master mix was prepared with Hot FirePol Polymer-
ase and EvaGreen from Solis Biodyne (Tartu, Estonia) and
gene-speciﬁc primers for bcl-2 (forward: CCCAAGTTTTGAGCCATT-
CA, reverse: CCTGGTGGACAACATCGC), CXCR4 (forward: CGTGGA
ACGTTTTTCCTGTT, reverse: GGTGCTGAAATCAACCCACT), and RNA
polymerase II (forward: GAAGGCACTCTCCAGGTTTG, reverse:
ATGCTGGTTTTGGTGACGAC) as reference gene from Microsynth
(Basel, Switzerland). Primer design was done in compliance with
the Miqe guidelines32 using the online tools Primer3Plus, mFOLD
(amplicon total DGP 3.0; no secondary structures at the primer
binding side), NetPrimer (no hairpins; dimer DGP 6.0; cross di-
merDGP 6.0), and PrimerBlast; see Supplementary information.
Standard curves for determination of the reaction efﬁciencies were
prepared by making serial dilutions of the untreated reference
cDNA. PCR reactions were run on a Roche Light Cycler 480 (Roche,
Mannheim, Germany) with two technical replicates for each sam-
ple. Cp values and reaction efﬁciencies (bcl-2: 0.864, CXCR4: 0.946,
RNA polymerase II: 1.078) were determined using the Light Cycler
software. The relative expression of bcl-2 normalized to the refer-
ence gene and the standard errors were calculated with REST 2009
software (Qiagen, Hilden, Germany).
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